{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:44:37Z","timestamp":1775097877748,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Invivyd, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40121-026-01315-6","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T13:01:28Z","timestamp":1771246888000},"page":"1007-1017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19"],"prefix":"10.1007","volume":"15","author":[{"given":"Ilker","family":"Yalcin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leijun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandyn","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Wingertzahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"4","key":"1315_CR1","first-page":"767","volume":"70","author":"D Hobson","year":"1972","unstructured":"Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767\u201377.","journal-title":"J Hyg (Lond)"},{"key":"1315_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-18","volume":"10","author":"L Coudeville","year":"2010","unstructured":"Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010;10:18.","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"1315_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205\u201311.","journal-title":"Nat Med"},{"issue":"688","key":"1315_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg2783","volume":"15","author":"P Schmidt","year":"2023","unstructured":"Schmidt P, Narayan K, Li Y, et al. Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci Transl Med. 2023;15(688):eadg2783.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1315_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40204-1","volume":"14","author":"E Stadler","year":"2023","unstructured":"Stadler E, Burgess MT, Schlub TE, et al. Monoclonal antibody levels and protection from COVID-19. Nat Commun. 2023;14(1):4545.","journal-title":"Nat Commun"},{"issue":"19","key":"1315_CR6","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMc2404555","volume":"391","author":"P Schmidt","year":"2024","unstructured":"Schmidt P, Li Y, Popejoy M. Immunobridging for pemivibart, a monoclonal antibody for prevention of COVID-19. N Engl J Med. 2024;391(19):1860\u20132.","journal-title":"N Engl J Med"},{"key":"1315_CR7","unstructured":"Invivyd. Fact sheet for healthcare providers: emergency use authorization of PEMGARDA (Pemivibart). Updated September 2025. https:\/\/www.fda.gov\/media\/177067\/download?attachment. Accessed 5 Jan 2026."},{"issue":"7","key":"1315_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad314","volume":"10","author":"MG Ison","year":"2023","unstructured":"Ison MG, Weinstein DF, Dobryanska M, et al. Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a phase\u00a02\/3 randomized, double-blind, placebo-controlled trial (EVADE). Open Forum Infect Dis. 2023;10(7):ofad314.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1315_CR9","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1038\/s41467-023-39292-w","volume":"14","author":"D Follmann","year":"2023","unstructured":"Follmann D, O\u2019Brien MP, Fintzi J, et al. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat Commun. 2023;14(1):3605.","journal-title":"Nat Commun"},{"issue":"3","key":"1315_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","volume":"185","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467\u201384.","journal-title":"Cell"},{"key":"1315_CR11","unstructured":"AstraZeneca. Fact sheet for healthcare providers: emergency use authorization for EVUSHELD (tixagevimab co-packaged with cilgavimab). January 2023. 2023. https:\/\/www.fda.gov\/media\/154701\/download. Accessed 5 Jan 2026."},{"key":"1315_CR12","doi-asserted-by":"crossref","unstructured":"Haidar G, Thomas S, Loubet P, et al. Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase\u00a03 trial. Lancet Infect Dis. 2025;25(7):813\u201326.","DOI":"10.1016\/S1473-3099(24)00804-1"},{"key":"1315_CR13","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2024. https:\/\/www.R-project.org\/. Accessed 5 Jan 2026."},{"issue":"3","key":"1315_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/cid\/ciaf265","volume":"81","author":"CR Wolfe","year":"2025","unstructured":"Wolfe CR, Cohen J, Mahoney K, et al. Safety and efficacy of pemivibart, a long-acting monoclonal antibody, for prevention of symptomatic COVID-19: interim results from a phase\u00a03 randomized clinical trial (CANOPY). Clin Infect Dis. 2025;81(3):439\u201350. https:\/\/doi.org\/10.1093\/cid\/ciaf265.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1315_CR15","doi-asserted-by":"publisher","first-page":"9101","DOI":"10.1038\/s41467-025-63972-","volume":"16","author":"R Edge","year":"2025","unstructured":"Edge R, Matthews S, Ahani B, et al. A SARS-CoV-2 variant-adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19. Nat Commun. 2025;16(1):9101. https:\/\/doi.org\/10.1038\/s41467-025-63972-.","journal-title":"Nat Commun"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01315-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:50:21Z","timestamp":1775094621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01315-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01315-6","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors were employees of Invivyd, Inc. (Ilker Yacin, Brandyn West, Kristin Narayan, Anna Holmes, Mark Wingertzahn) or contractors of Invivyd, Inc. (Leijun Hu) at the time this research was conducted and may hold stock or shares in Invivyd, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The CANOPY trial was conducted in accordance with the International Council for Harmonization guideline on Good Clinical Practice, the principles of the Declaration of Helsinki, and all applicable regulations. Written informed consent was obtained from all participants for participation in the study and publication. The protocol was approved by Advarra IRB, Reference Code Pro00070754, and has been published previously [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}},{"value":"New author affiliations include Anna Holmes, Peptilogics, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}